![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany (J.W., A.S.); and Institute of Pharmacy and Food Chemistry, Department of Pharmaceutical Chemistry, University of Würzburg, Würzburg, Germany (A.F., M.U.)
Root extracts from kava-kava (Piper methysticum G. Forst) are clinically used for the treatment of anxiety and restlessness. Due to reported cases of liver toxicity, kava-kava extracts were withdrawn from the market in several countries in 2002. Because the efflux transporter P-glycoprotein (P-gp) is involved in the absorption, distribution, and excretion of many drugs and often participates in drug-drug interactions, we studied the effect of a crude kava extract and the main kavalactones kavain, dihydrokavain, methysticin, dihydromethysticin, yangonin, and desmethoxyyangonin on the P-gp-mediated efflux of calcein-acetoxymethylester in the P-gp-overexpressing cell line P388/dx and the corresponding cell line P388. The crude extract and the kavalactones showed a moderate to potent inhibitory activity with f2 (concentration needed to double baseline fluorescence) values of 170 µg/ml and 17 to 90 µM, respectively. The f2 value of yangonin could not be determined due to its higher lipophilicity. In conclusion, our results for the first time demonstrate P-gp-inhibitory activity of kava-kava and its components in vitro.
This article has been cited by other articles:
![]() |
B. J. Gurley, A. Swain, G. W. Barone, D. K. Williams, P. Breen, C. R. Yates, L. B. Stuart, M. A. Hubbard, Y. Tong, and S. Cheboyina Effect of Goldenseal (Hydrastis canadensis) and Kava Kava (Piper methysticum) Supplementation on Digoxin Pharmacokinetics in Humans Drug Metab. Dispos., February 1, 2007; 35(2): 240 - 245. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Weiss and W. E. Haefeli EVALUATION OF INHIBITORY POTENCIES FOR COMPOUNDS INHIBITING P-GLYCOPROTEIN BUT WITHOUT MAXIMUM EFFECTS: F2 VALUES Drug Metab. Dispos., February 1, 2006; 34(2): 203 - 207. [Abstract] [Full Text] [PDF] |
||||